The abstract is read at the publisher; the summary is JClub's.
In a Lyon referral-center cohort of 31 adult Candida periprosthetic joint infection patients (2017–2024), infection control was achieved in 23/31 (74.1%) at end of follow-up.
- Why it matters: Candida cPJI are poorly characterized, leaving uncertainty about how antifungal management, therapeutic drug monitoring, surgery, and outcomes relate in complex prosthetic histories.
- What they did: This retrospective single-center study used the 2021 EBJIS definition and assessed outcomes at 1, 3, and 12 months; 96.8% received systemic antifungals and 83.9% had TDM.
- The result: Most patients (74.1%) reached infection control, with care typically combining systemic antifungal therapy, surgery when feasible, and TDM-guided follow-up, including suppressive therapy in 50%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.